Exact Sciences (NASDAQ: EXAS) is on a bit of an acquisition spree. Having closed its acquisition of Genomic Health in November, the diagnostic test maker announced it was buying two privately held cancer diagnostic companies, Paradigm Diagnostics and Viomics, on Tuesday after the closing bell.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,